Trial Profile

A Phase I Study Of UCN-01 In Combination With Irinotecan In Resistant Solid Tumor Malignancies (Part I) and in Triple Negative (ER [estrogen receptor]-Negative, PgR [progesterone receptor]-Negative, HER-2 Not Amplified) Recurrent Breast Cancers (Part II).

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 09 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Irinotecan (Primary) ; UCN 01 (Primary)
Indications Advanced breast cancer; Cervical cancer; Endometrial cancer; Gastrointestinal cancer; Head and neck cancer; Lung cancer; Ovarian cancer; Prostate cancer; Solid tumours
Focus Adverse reactions; Therapeutic Use

01 Jul 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
06 Nov 2012 Status changed from completed to active, no longer recruiting as reported by ClinicalTrials.gov.
10 May 2012 Actual end date (January 2011) added as reported by ClinicalTrials.gov.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com